Three biopharma companies recently shuttered their clinical programs after either their drug compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints.
Bristol Myers Squibb’s experimental psoriasis drug deucravacitinib (BMS-986165) beat out Amgen’s Otezla (apremilast) in the POETYK PSO-1 Phase III clinical trial.
U.S. health experts this week will decide whether to recommend approval for Biogen Inc.’s experimental Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if the antibody aducanumab works.
Less than a month after the failure of a Phase III Duchenne muscular dystrophy (DMD) trial, Switzerland-based Santhera Pharmaceuticals announced a corporate restructuring that includes the termination of 50 percent of the company’s workforce.
A small but key UK study found that “cellular immunity” to the pandemic SARS-CoV-2 virus is present after six months in people who had mild or asymptomatic Covid-19, suggesting they might have some level of protection for at least that time.
CureVac’s experimental Covid-19 vaccine triggered an immune response in humans, putting the German biotech firm on track to start mass testing during 2020 as the race to end the pandemic heats up.
Japan’s Sosei Group Corp. is allying with a U.S. biotech run by former Novartis AG executives to commercialize a neurological drug pipeline.
(Reuters) – AstraZeneca Plc said on Sunday Britain’s health regulator had started an accelerated review of its potential coronavirus vaccine. “We confirm the MHRA’s (Medicines and Healthcare Products Regulatory Agency) […]
Novo Nordisk ended development of the anti-IL-21 antibody NN9828 in combination with Victoza after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
Johnson & Johnson plans to start testing the company’s experimental Covid-19 vaccine in youths aged 12 to 18 as soon as possible, a company executive said at a meeting held by the U.S. Centers for Disease Control and Prevention (CDC).
